Social Anxiety in Schizophrenia: An Overlooked Problem
Emerging evidence has begun to elucidate the prevalence and outcomes associated with social anxiety disorder in schizophrenia.
Schizophrenia and Psychoses
SCHIZOPHRENIA AND PSYCHOSES
Featured Article
Latest News
Early Placebo Improvement May Be a Marker for Long-Term Placebo Response in Schizophrenia Trials
Investigators examine patients who demonstrated improvement after placebo injections and aimed to determine criteria to predict subsequent response.
Guanfacine Augmentation for Cognitive Therapy Effective for Schizotypal Personality Disorder
Augmentation with guanfacine alongside cognitive remediation and social skills may be an effective intervention for patients with schizotypal personality disorder.
High Religiosity, Polygenic Risk Score Influence Religious Delusions in Schizophrenia
Strong religious activity and high polygenic schizophrenia risk scores are independent risk factors for religious delusions in schizophrenia and schizoaffective disorder.
FDA: Important Updates to the Clozapine REMS Program
Products covered under the Clozapine REMS program include Clozaril (HLS Therapeutics), Fazaclo (Jazz), and Versacloz (TruPharma), in addition to all generic versions.
Smoking Associated With Worsened Symptoms, Quality of Life in Patients With Psychosis
A negative association between number of cigarettes per day and quality of life was observed in patients with psychosis.
Schizophrenia Risk Alleles, Peer Victimization Associated With Emotional Problems in Youth
Peer victimization may be an important modifiable factor in improving the developmental course among children.
Interaction Observed Between Age, Treatment Outcomes for Long-Acting Injectable Antipsychotic Medications
Researchers investigated subgroup responses to long-acting injectable medications haloperidol decanoate and paliperidone palmitate.
Immune Variations Appear to Be Unrelated to Psychosis, Schizophrenia
Examination of raw data does not show a multi-modal distribution of immune parameter data in patients.
Schizophrenia Add-Ons: Beware the Flawed Meta-Analyses Touting Improvements
Clinicians should be discerning when evaluating meta-analyses of schizophrenia add-on therapies such as statins and antidepressants.
Aberrant Epstein-Barr Virus Response Associated With Schizophrenia
Investigators confirmed that people with schizophrenia have higher levels of antibodies to some but not all Epstein-Barr virus proteins, which indicates an aberrant response to Epstein-Barr virus infection that may be a factor in the immunopathology of schizophrenia and related disorders.
Want to read more?
Please login or register first to view this content.
Next post in Schizophrenia and Psychoses
